Altamira Therapeutics (NASDAQ:CYTO) randomized the first group of patients in a clinical trial with Bentrio (AM-301) in house dust mite allergic rhinitis.
Bentrio, a drug-free nasal spray intended for personal protection against airborne viruses and allergens, is marketed in several countries already.
The trial will enroll 36 patients with a history of perennial allergic rhinitis. It is designed to evaluate the efficacy of Bentrio in the treatment of perennial allergic rhinitis in an environmental exposure chamber, which is under controlled house dust mite exposure.
Study participants will be randomized under an open label, three-period crossover design to receive either Bentrio in a single or double dose or no treatment prior to house dust mite exposure for three hours. The primary endpoint will be the change in the Total Nasal Symptom Score from baseline. The trial is being conducted at a single study site in Canada.
“Following the positive outcomes from our previous controlled pollen exposure study in seasonal allergic rhinitis, we expect this new study to demonstrate Bentrio’s protective effects also in perennial allergic rhinitis,” Thomas Meyer, Altamira’s founder, chairman and CEO, said in a statement.
Allergic rhinitis in both its seasonal and perennial form is a very common problem worldwide. “We believe that Bentrio can help to provide important relief for many allergy sufferers based on its triple mode of action, free of any drug or preservative ingredients,” he added.
Top-line results from the house dust mite trial are expected to become available in the spring of 2022.
